Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3011 | Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol Wiki | 0.71 |
drug2490 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D003922 | Diabetes Mellitus, Type 1 NIH | 0.24 |
D003920 | Diabetes Mellitus, NIH | 0.14 |
D018352 | Coronavirus Infections NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100651 | Type I diabetes mellitus HPO | 0.25 |
HP:0000819 | Diabetes mellitus HPO | 0.14 |
Navigate: Correlations HPO
There are 2 clinical trials
This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.
Description: Occurrence of adverse reactions within 7 days after vaccination Percentage of subjects with ≥ Grade 3 adverse events within 7 days after vaccination
Measure: Safety of UB-612 vaccine Time: 7 days following vaccinationDescription: Occurrence of adverse events (AEs) till Day 56 Occurrence of serious adverse events (SAEs) till Day 56
Measure: Safety Time: Day 0 to Day 56Description: Occurrence of serious adverse events during the whole follow-up period
Measure: Safety Time: Day 29 to Day 196Description: Occurrence of adverse events of special interest during the study period
Measure: Safety Time: Day 0 to Day 196Description: Geometric mean titer (GMT) of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196Description: Seroconversion rate (SCR) of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196Description: Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)
Measure: Immunogenicity Time: Day 14, 28, 42, 56, 112, and 196This is a Phase 2/3, randomized, multicenter, double-blind, dose-response study to evaluate the safety, immunogenicity, and efficacy of UB 612 in 2 age groups, adults 18 to 59 and ≥60 years of age with or without comorbidities.
Description: Safety and Tolerability
Measure: The incidence of local reactions, solicited systemic events, AEs, MAAEs, SAEs and AESIs Time: Day 1 to 24 monthsDescription: Percentage of subjects with changes in lab values at different time points
Measure: Change in safety chemistry blood lab values for assessment of risk in Phase 3 Time: Phase 2 -Day 1 to Day 36Description: Percentage of subjects with changes in lab values at different time points
Measure: Change in safety hematology blood lab values for assessment of risk in Phase 3 Time: Phase 2 -Day 1 to Day 36Description: SARS-CoV-2 incidence based on qPCR nasopharyngeal swab
Measure: Prevention of SARS-CoV-2 infection in adults Time: Day 29 to 24 MonthDescription: Immunogenicity of UB-612 vaccine
Measure: Change after second dose through the end of study in antibody titers Time: Month 1, 6, 12 and 24 following Dose 2Description: COVID-19 incidence confirmed by qPCR nasopharyngeal swab
Measure: Prevention of COVID-19 in adults Time: Day 42 to 24 MonthDescription: Efficacy of UB-612 vaccine
Measure: Reduction in severity of COVID-19 in adults Time: Day 42 to 24 MonthDescription: Efficacy of UB-612 vaccine
Measure: Prevention of COVID-19 death in adults Time: Day 42 to 24 MonthDescription: Measured by comparing the SARS-CoV-2 shedding in vaccine and placebo subjects
Measure: Change in SARS CoV-2 shedding Time: Day 42 to 24 MonthDescription: Number of cytokine secreting spots
Measure: Immunogenicity of UB-612 vaccine in young and older adults, with or without comorbidities, and no serological or virological evidence of past infection with SARS-CoV-2 Time: baseline, 7 days, 6, 12, and 24 months after Dose 2Description: Efficacy of UB-612 vaccine
Measure: Change in SARS CoV-2 infection Time: Month 1, 6, 12 and 24 following Dose 2Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports